Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Arrogance and Greed: Ackman, Valeant Pay $290M to End Allergan Insider Trading Lawsuit January 1, 2018 Torrent Pharma Coughs Up $558M for Unichem's India Biz November 2, 2017 Takeda Showcases Broadened Oncology Portfolio Through Data Presentations At Upcoming Medical Meetings May 23, 2017
Arrogance and Greed: Ackman, Valeant Pay $290M to End Allergan Insider Trading Lawsuit January 1, 2018
Takeda Showcases Broadened Oncology Portfolio Through Data Presentations At Upcoming Medical Meetings May 23, 2017
